Capital Group Investment Management PTE. LTD. Has $2.53 Million Position in Royalty Pharma PLC $RPRX

Capital Group Investment Management PTE. LTD. increased its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 44.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 65,513 shares of the biopharmaceutical company’s stock after acquiring an additional 20,168 shares during the period. Capital Group Investment Management PTE. LTD.’s holdings in Royalty Pharma were worth $2,531,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Lloyd Advisory Services LLC. acquired a new stake in shares of Royalty Pharma during the 4th quarter valued at about $30,000. Smartleaf Asset Management LLC boosted its position in shares of Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 790 shares in the last quarter. Private Trust Co. NA boosted its position in shares of Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 288 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 306 shares in the last quarter. Finally, Fifth Third Bancorp boosted its position in shares of Royalty Pharma by 16.9% during the 3rd quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 362 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Trading Up 1.5%

Shares of NASDAQ RPRX opened at $55.87 on Friday. Royalty Pharma PLC has a 1-year low of $33.37 and a 1-year high of $56.07. The company has a market cap of $32.17 billion, a PE ratio of 38.01, a P/E/G ratio of 1.54 and a beta of 0.43. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The company has a 50-day moving average of $50.81 and a two-hundred day moving average of $45.01.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The company had revenue of $630.58 million during the quarter, compared to the consensus estimate of $881.69 million. As a group, equities analysts expect that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $0.235 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.7%. Royalty Pharma’s payout ratio is currently 63.95%.

Wall Street Analysts Forecast Growth

RPRX has been the subject of several analyst reports. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Citigroup lifted their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Weiss Ratings downgraded shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. The Goldman Sachs Group reissued a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. Finally, UBS Group lifted their price target on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Royalty Pharma currently has a consensus rating of “Buy” and an average price target of $53.71.

Insiders Place Their Bets

In other Royalty Pharma news, CFO Terrance P. Coyne sold 64,399 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $53.98, for a total value of $3,476,258.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the business’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.06, for a total transaction of $726,073.04. Following the completion of the transaction, the executive vice president directly owned 31,881 shares of the company’s stock, valued at approximately $1,691,605.86. This represents a 30.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 199,185 shares of company stock valued at $10,082,926. Insiders own 18.84% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.